Aims: The overall objective of the Core is to offer the biochemical and thrombosis support to all the individual projects of the SCOR. This Core will be responsible for the performance and evaluation of the studies involving blood thrombogenicity with Badimon perfusion chamber and all the different hematological and biochemical parameters required for the development of the different projects included in the present SCOR application. The Clinical Project (Dr. V. Fuster) includes approximately 500 perfusion studies. The cohorts of diabetic (n=50) and hyperlipidemic (n=50) patients will be studied at baseline and 3-, 9- and 18- months after treatment initiation; the smokers will be studied at baseline and 4-weeks after smoking cessation). These patients will be monitored for plasma levels of TFPI, TF antigen and activity, C-Reactive Protein at baseline, 3, 9 and 18-months after treatment initiation. In addition, the Core will also be responsible for the determination of TIPI and TF antigen and activity in the samples obtained through our collaboration with the investigators of the REVERSAL and WOMEN'S HEALTH STUDY (See Dr. Fuster's Project). The core will be responsible for the determination and management of the biochemical data of the hyperlipidemic, and diabetic and smokers involved in the Clinical Project (D. V. Fuster). The Core will also be responsible for all the blood thrombogenicity studies described in Dr. Taubman's and Nemerson's project as well as the determination of plasma levels of TF antigen and activity, TIPI, C-Reactive Protein and Troponin-I in the experimental studies of this project. The Core will also monitor the levels of anticoagulation (aPTT, PTT, TT) and the blood cell count (by using a cell counter equipped with veterinarian software) of the animals from Taubman's project and cholesterol levels from Dr. Harpel's project.
| Johnson-Huang, Leanne M; Suárez-Fariñas, Mayte; Sullivan-Whalen, Mary et al. (2010) Effective narrow-band UVB radiation therapy suppresses the IL-23/IL-17 axis in normalized psoriasis plaques. J Invest Dermatol 130:2654-63 |
| Choi, Brian G; Vilahur, Gemma; Zafar, M Urooj et al. (2008) Selective estrogen receptor modulation influences atherosclerotic plaque composition in a rabbit menopause model. Atherosclerosis 201:76-84 |
| Worthley, Stephen G; Helft, Gerard; Corti, Roberto et al. (2007) Statin therapy alone and in combination with an acyl-CoA:cholesterol O-acyltransferase inhibitor on experimental atherosclerosis. Pathophysiol Haemost Thromb 36:9-17 |
| Corti, Roberto; Osende, Julio; Hutter, Randolph et al. (2007) Fenofibrate induces plaque regression in hypercholesterolemic atherosclerotic rabbits: in vivo demonstration by high-resolution MRI. Atherosclerosis 190:106-13 |
| Choi, Brian G; Novoselsky, Constantin A; Vilahur, Gemma et al. (2007) Validation study of a semi-automated program for quantification of atherosclerotic burden. J Cardiovasc Magn Reson 9:615-20 |
| White, R James; Meoli, David F; Swarthout, Robert F et al. (2007) Plexiform-like lesions and increased tissue factor expression in a rat model of severe pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 293:L583-90 |
| Hathcock, James; Rusinova, Elena; Vaananen, Heikki et al. (2007) Lipid-bound factor Xa regulates tissue factor activity. Biochemistry 46:6134-40 |
| Khorana, Alok A; Ahrendt, Steven A; Ryan, Charlotte K et al. (2007) Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res 13:2870-5 |
| Pyo, Robert T; Sui, Jinliang; Dhume, Ashwini et al. (2006) CXCR4 modulates contractility in adult cardiac myocytes. J Mol Cell Cardiol 41:834-44 |
| Bogdanov, V Y; Kirk, R I; Miller, C et al. (2006) Identification and characterization of murine alternatively spliced tissue factor. J Thromb Haemost 4:158-67 |
Showing the most recent 10 out of 91 publications
